- Home
- BSM vs CELC Comparison
BSM vs CELC Comparison
Compare BSM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | CELC |
|---|---|---|
| Founded | 1876 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BSM | CELC |
|---|---|---|
| Price | $14.32 | $120.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $14.00 | ★ $112.56 |
| AVG Volume (30 Days) | 382.1K | ★ 669.5K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,919,000.00 | N/A |
| Revenue This Year | $11.03 | N/A |
| Revenue Next Year | $9.63 | $720.19 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $11.90 | $9.64 |
| 52 Week High | $15.49 | $129.09 |
Technical Indicators
Market Signals| Indicator | BSM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 52.97 |
| Support Level | $13.41 | $99.38 |
| Resistance Level | $15.33 | N/A |
| Average True Range (ATR) | 0.28 | 6.84 |
| MACD | 0.08 | -0.42 |
| Stochastic Oscillator | 89.01 | 64.90 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.